Recent patient trials surrounding the medication Retatrutide , specifically the 120mg formulation referred to as ZPHC, suggest a impressive impact on weight decrease and associated metabolic factors. Experts believe that this dual agonist , targeting both GLP-1 and GIP pathways , could provide a